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Abstract
Dabigatran and rivaroxaban are novel oral anticoagulants that specifically inhibit thrombin and factor Xa, respectively. The
aim of this study is to elucidate antithrombotic properties of these anticoagulant agents under arterial and venous shear
conditions. Whole blood samples treated with dabigatran or rivaroxaban at 250, 500, and 1000 nM, with/without aspirin
and AR-C66096, a P2Y12 antagonist, were perfused over a microchip coated with collagen and tissue thromboplastin at
shear rates of 240 and 600 s21. Fibrin-rich platelet thrombus formation was quantified by monitoring flow pressure changes.
Dabigatran at higher concentrations (500 and 1000 nM) potently inhibited thrombus formation at both shear rates, whereas
1000 nM of rivaroxaban delayed, but did not completely inhibit, thrombus formation. Dual antiplatelet agents weakly
suppressed thrombus formation at both shear rates, but intensified the anticoagulant effects of dabigatran and rivaroxaban.
The anticoagulant effects of dabigatran and rivaroxaban were also evaluated under static conditions using thrombin
generation (TG) assay. In platelet-poor plasma, dabigatran at 250 and 500 nM efficiently prolonged the lag time (LT) and
moderately reduce peak height (PH) of TG, whereas rivaroxaban at 250 nM efficiently prolonged LT and reduced PH of TG.
In platelet-rich plasma, however, both anticoagulants efficiently delayed LT and reduced PH of TG. Our results suggest that
dabigatran and rivaroxaban may exert distinct antithrombotic effects under flow conditions, particularly in combination
with dual antiplatelet therapy.
Citation: Hosokawa K, Ohnishi T, Sameshima H, Miura N, Koide T, et al. (2014) Comparative Evaluation of Direct Thrombin and Factor Xa Inhibitors with
Antiplatelet Agents under Flow and Static Conditions: An In Vitro Flow Chamber Model. PLoS ONE 9(1): e86491. doi:10.1371/journal.pone.0086491
Editor: Rizwan H. Khan, Aligarh Muslim University, India
Received July 31, 2013; Accepted December 10, 2013; Published January 31, 2014
Copyright:  2014 Hosokawa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: Kazuya Hosokawa, Tomoko Ohnishi, Hisayo Sameshima are employees of Fujimori Kogyo, the manufacturer of the T-TAS. This does not
alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: tanakak@upmc.edu
Introduction
Oral anticoagulants, dabigatran, a direct thrombin inhibitor
(anti-IIa), and rivaroxaban, a direct factor Xa inhibitor (anti-Xa)
represent novel therapeutic strategies for the prevention of deep
vein thrombosis, and for the stroke prevention in atrial fibrillation
[1]. In contrast to vitamin K antagonists, which typically require a
titration using prothrombin time, these anticoagulants demon-
strate predictable pharmacokinetics and anticoagulant responses,
allowing for a fixed dosing regimen without routine monitoring
[2,3]. However, an option to assess the extent of anticoagulation is
needed for patients with active bleeding associated with acute
intestinal bleeding, trauma, and for those who require urgent
invasive procedures [4,5].
The combination of anticoagulant and antiplatelet therapies is a
potential treatment strategy for acute coronary syndrome (ACS)
because thrombin generation and fibrin formation can occur
within the platelet thrombus during acute coronary events. It has
been suggested that the addition of anti-IIa or anti-Xa agent to
antiplatelet therapy may improve clinical outcomes after ACS [6–
10]. However, these combination therapies are often associated
with the increased risk of bleeding complications, implicating a
relatively narrow therapeutic dose window [8–10]. It is, therefore,
clinically important to individually assess residual hemostatic
functions by testing anticoagulant and antiplatelet agents under
the same conditions. However, this is not feasible using
conventional platelet function assays and coagulation tests [11].
Some of the latter limitations may be overcome by evaluating
fibrin-rich platelet thrombus formation under flow conditions [12].
In the present study, we evaluated the antithrombotic efficacies
of dabigatran and rivaroxaban alone or in combination with
antiplatelet agents by analyzing in vitro thrombus formation
patterns under arterial and venous shear conditions in a flow-
chamber system. A thrombin generation (TG) assay was
performed in parallel to evaluate and characterize the effects of
both anticoagulants under static conditions.
Materials and Methods
Materials
The cover and capillary chips used in the flow chamber system
(Fig. S1A) were manufactured by Richell Corp. (Toyama, Japan).
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The following materials were obtained from commercial sources:
porcine type I collagen (Nitta Gelatin, Inc., Osaka, Japan), tissue
thromboplastin (Sysmex, Hyogo, Japan), fluorescein isothiocya-
nate (FITC)-conjugated mouse anti-human CD41 immunoglobu-
lin G (IgG), and FITC-conjugated mouse IgG (Beckman Coulter,
Miami, FL, USA), rabbit anti-human fibrinogen IgG (Dako,
Tokyo, Japan), normal rabbit IgG (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and Alexa594 (Invitrogen, Carlsbad, CA,
USA).
Dabigatran and rivaroxaban were obtained from Toronto
Research Chemicals, Inc. (Toronto, Canada). AR-C66096, a
specific P2Y12-receptor antagonist, was obtained from Tocris
Bioscience (Bristol, UK). For the TG assay, PPP-Reagent (with
phospholipids), PRP-Reagent (without phospholipids), and FluCa-
reagent, a fluorogenic substrate (Z-Gly-Gly-Arg-AMC) dissolved
in HEPES buffer and calcium chloride, were purchased from
Diagnostica Stago (Parsippany, NJ). Recombinant TF (r-TF) was
purchased from Mitsubishi Chemical Medience (Tokyo, Japan).
All other reagents were obtained from Wako Pure Chemicals
(Osaka, Japan). Corn trypsin inhibitor (CTI) was prepared as
reported previously [13].
Blood samples
The study protocol was approved by the local ethics committee
of Kinki University (Osaka, Japan), and informed written consent
was obtained from 15 healthy, fasting volunteers (9 males, 6
females; mean age, 35.067.8 years). No subjects had taken any
medication that might affect platelet function or coagulation in the
preceding two weeks of blood collection. Blood samples were
collected into plastic tubes containing 3.2% sodium citrate
(Terumo, Tokyo, Japan), and were then mixed with CTI (final
concentration, 50 mg mL21). Citrated whole-blood samples were
spiked with either dabigatran (250, 500, or 1000 nM) or
rivaroxaban (250, 500, or 1000 nM) with or without the dual
antiplatelet agents, aspirin (100 mM) and AR-C66096 (1 mM).
Dimethyl sulfoxide was used as the solvent (,0.1%, final
concentration) for dabigatran, rivaroxaban and aspirin. This agent
had no effect on flow chamber measurements at concentrations of
up to 0.1%. The total volume of the added antithrombotic agents
was less than 1% of the total blood volume.
Preparation of microchips coated with collagen and
thromboplastin
A section (15615 mm) of each cover chip (Fig. S1A) was coated
with type I collagen (1.5 mg mL21) and tissue thromboplastin
dissolved in 1 mM HCl. Both high thromboplastin (HTP; 100 mg
mL21) and low thromboplastin (LTP; 25 mg mL21) were used to
assess the impact of thromboplastin levels on the antithrombotic
effects of dabigatran and rivaroxaban. The coated side of the cover
chip was sealed with the capillary chip for 16 h at 60uC.
Evaluation of thrombus formation under flow conditions
Thrombus formation under flow was evaluated using the T-
TAS (Fujimori Kogyo, Kanagawa, Japan) as previously described
[11]. The T-TAS system is equipped with a rectangular capillary
(width, 300 mm; depth, 80 mm; length 15 mm), a pneumatic
pump, and a flow pressure sensor (Fig. S1B). For the analysis,
recalcified CTI-treated whole blood was perfused at 37uC through
the pre-coated microcapillary-chamber (HTP or LTP as above).
Flow pressure changes were monitored using the pressure
transducer located upstream of the microcapillary chamber.
During the perfusion of blood through the flow chamber, platelets
and plasma coagulation pathways are simultaneously activated by
collagen and tissue thromboplastin. Thrombus formation and
breakdown within microcapillary results in flow disturbances,
causing an increase and decrease of the pressure, respectively. At
flow rates of 4 and 10 ml min21, the initial wall shear rates were
estimated to be 240 and 600 s21, respectively according to the
FLUENT program (Ansys Co., Ltd., Tokyo, Japan). These shear
rates correspond to normal shear rates in large arteries and small
veins (240 s21), and those of medium-sized arteries (600 s21) [14].
Endpoint parameters were as follows: (i) T10 (time to 10 kPa)
represents the interval for the flow pressure to increase by 10 kPa
from baseline due to the partial occlusion of the capillary; (ii) OT
(occlusion time) represents the interval for the flow pressure to
increase by 80 kPa from baseline due to the complete capillary
occlusion; (iii) AUC30 (area under the curve for 30 min) represents
the area under the flow pressure curve (below 80 kPa) for 30 min
after the start of perfusion.
Analysis of thrombi by confocal microscopy
Changes in the composition of thrombi due to dabigatran
(500 nM) without/with antiplatelet agents were evaluated using
immunostaining followed by confocal laser scanning microscopy.
The thrombus specimen was collected from the mid-segment of
the capillary, washed three times with phosphate-buffered saline
(PBS), and then incubated with fluorescein isothiocyanate (FITC)-
conjugated mouse anti-human CD41 (platelet glycoprotein IIb)
IgG (1:6 dilution) at room temperature for 15 min in the dark.
FITC-conjugated mouse IgG was used as a control. After three
washes with Tris-buffered saline containing 0.1% Triton X-100
(TBST), the thrombus was immobilized with OptiLyse C (Beck-
man Coulter, France) for 15 min at room temperature. After three
additional washes with TBST, the sample was blocked for 1 h at
room temperature with Block Ace (Yukijirushi, Osaka, Japan)
containing 1 mg mL21 normal goat IgG. The sample was then
incubated with rabbit anti-human fibrinogen IgG (1:99 dilution)
labeled with Alexa 594 at room temperature for 30 min in the
dark. Alexa 594-conjugated rabbit IgG was used as a control. The
prepared thrombi specimens were examined using an LSM700
confocal microscope (Zeiss, Germany).
Effects of antithrombotic agents on thrombin generation
Citrated blood samples were centrifuged at 125 x g and 1,760
x g for 10 min at room temperature to prepare platelet-rich plasma
(PRP) and platelet-poor plasma (PPP), respectively. The platelet
count in PRP was adjusted to 1506103 mL21 using autologous
PPP. To prevent contact phase activation, PRP and PPP were
mixed with CTI (final concentration, 50 mg mL21). For TG
experiments, 20 ml of PPP-Reagent (1pM or 5 pM) and PRP-
Reagent were mixed with 80 ml PPP and PRP, respectively, in 96-
well round-bottom microtiter plates (Thermo Fisher Scientific,
Waltham, MA, USA). The final concentration of r-TF was 1 pM
in PRP, whereas r-TF concentrations of 1 and 5 pM were tested
for PPP. The plate was inserted into a Fluoroskan AscentH
fluorometer (ThermoLabsystem, Helsinki, Finland), and then
warmed to 37uC for 5 min. TG experiments were initiated by
automatically dispensing 20 ml of 2.5 mM fluorogenic substrate in
0.1 M CaCl2 to each well. Measurements were performed in
duplicate for each experiment [15]. For each TG measurement,
lag time (LT, min), peak thrombin concentration (PH, nM), and
the endogenous thrombin potential (ETP, area under the TG
curve, min x nM) were evaluated using the Thrombinoscope
software (Thrombinoscope BV, Maastricht, Netherlands).
Antithrombotic Interventions under Flow Conditions
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Statistical analysis
Data are shown as the mean 6 standard deviation (SD), unless
otherwise indicated. Differences between groups were tested by
one-way repeated ANOVA, followed by Tukey’s post-hoc test. To
assess the efficacy of antiplatelet reagents, we calculated the
relative ratio of OT values with and without antiplatelet agents
(OT+antiplatelet/OT-antiplatelet) for dabigatran and rivaroxaban. The
measured OT ratios at different concentrations were averaged to
assess the difference between dabigatran and rivaroxaban. All
statistical analysis were performed using Prism version 5.02
software (GraphPad Software, CA, USA). A P value of ,0.05
was considered statistically significant.
Results
Effects of tissue thromboplastin levels on thrombus
formation under flow conditions
At a shear rate of 240 s21, the onset (T10) and capillary
occlusion (OT) for control whole-blood samples perfused over
LTP-microchips were 8.5660.79 min and 12.7160.56 min,
respectively (Fig. 1A). For HTP-microchips at 240 s21, the T10
and OT values were 7.4460.32 min and 11.7160.52 min (Fig.
1B). Thrombus formation was accelerated in the control blood
samples at a shear rate of 600 s21. T10 and OT values for LTP-
microchips were 7.3660.24 min and 9.2660.37 min, respectively,
and those for HTP-microchips were 6.4360.30 min and
8.1260.34 min, respectively, at 600 s21 (Fig. 1A, B).
Antithrombotic effects of dabigatran and rivaroxaban
under flow conditions
Dabigatran and rivaroxaban suppressed thrombus formation at
both examined shear rates in a concentration-dependent manner
for LTP- and HTP-microchips (Fig. 1A, B). Using LTP-
microchips, dabigatran at the concentration of 1000 nM almost
completely suppressed thrombus formation, as indicated by
prolonged OT and lower AUC, at both 240 and 600 s21, whereas
1000 nM rivaroxaban only moderately suppressed thrombus
formation (Fig. 1A). Compared to LTP-microchips, the
Figure 1. Effects of Dabigatran and Rivaroxaban on Thrombus Formation under Flow Conditions. The effects of dabigatran and
rivaroxaban on thrombus formation in the absence (panels A and B) and presence of aspirin/AR-C66096 (panels C and D) were evaluated using T-
TAS. Thrombus formation inside LTP (low thromboplastin) microchips (panels A and C) and HTP (high thromboplastin) microchips (panels B and
D). Data (n = 5) are shown as mean values. Shaded boxes indicate the values for T10 and/or OT exceeding 30 min, and the frequency of such
measurements is indicated above each box. AUC30, area under the curve for 30 min; OT, occlusion time; T10, time to 10 kPa.
doi:10.1371/journal.pone.0086491.g001
Antithrombotic Interventions under Flow Conditions
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e86491
Figure 2. Confocal Images of Immunostained Platelets and Fibrin. Immunostained thrombi in non-treated control blood (panel A), and in
the blood pre-treated with dabigatran (panel B), or dabigatran, aspirin, and AR-C66096 (AR-C) (panel C) after perfusion over the HTP (high
thromboplastin) microchips at 600 s21 are shown. For panels A, B and C, isotype-matched control (upper left), platelet GPIIb stained by anti-CD41-
FITC (green; upper right), fibrin stained by anti-fibrinogen-Alexa 594 (red; lower left), and a merged image (lower right) are shown.
doi:10.1371/journal.pone.0086491.g002
Figure 3. Effects of Dabigatran and Rivaroxaban on TG in PPP. The inhibitory effects of dabigatran (Dabi) and rivaroxaban (Riva) on thrombin
generation (TG) in platelet-poor plasma were evaluated using the ThrombinoscopeTM. Panel A: TG triggered by 1 pM recombinant tissue factor, and
Panel B: TG triggered by 5 pM recombinant tissue factor. Typical TG patterns reflecting distinctive efficacies of dabigatran and rivaroxaban are
shown.
doi:10.1371/journal.pone.0086491.g003
Antithrombotic Interventions under Flow Conditions
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prolongations of T10 and OT by both antithrombotic agents were
less extensive when HTP-microchips were used. In the whole
blood treated with 500 nM dabigatran, the OT values for LTP-
and HTP-microchips were prolonged by 2.36- and 1.95-fold,
respectively, at 240 s21, and by 2.27- and 1.99-fold, respectively,
at 600 s21. Similarly, 500 nM rivaroxaban increased OT values
for LTP- and HTP-microchips by 1.75- and 1.41-fold, respective-
ly, at 240 s21, and by 1.80- and 1.68-fold, respectively, at 600 s21
(Fig. 1A, B). Taken together, dabigatran appeared to inhibit
thrombus formation more potently than rivaroxaban regardless of
the tissue thromboplastin levels or shear rates.
Dual platelet inhibition using aspirin and AR-C66096 only
weakly suppressed thrombus formation, but enhanced the
antithrombotic efficacy of both dabigatran and rivaroxaban
(Fig. 1C, D). In terms of the ratio of OT (OT+antiplatelet/
OT-antiplatelet), dual anti-platelet agents increased OT values of
dabigatran- or rivaroxaban-treated blood by 1.48-fold and 1.20-
fold, respectively, as an average under all experimental conditions
(at high and low shear rates and at HTP and LTP concentrations).
This indicates that the antithrombotic activity of dabigatran is
more affected than that of rivaroxaban in the presence of aspirin
and AR-C66096 under arterial flow (Video S1).
Analysis of thrombi by confocal microscopy
The confocal images of thrombi formed at a shear rate of
600 s21 indicated progressive decreases in the intra-luminal
thrombus extension by dabigatran and dabigatran plus dual
antiplatelet inhibitions (Fig. 2).
Effects of dabigatran and rivaroxaban on endogenous TG
(i) TG in PPP. In TG measurements using PPP in the
presence of 1 pM r-TF, dabigatran at 500 nM prolonged LT and
TTP by 5.24- and 3.29-fold, respectively, and decreased PH by
25.0%, compared to the untreated control (Fig. 3A, Table 1).
Under the same conditions, rivaroxaban at 500 nM prolonged LT
and TTP by 3.05- and 2.88-fold, respectively, and reduced PH by
83.0%, of that of the control (Fig. 3A, Table 1). Similarly, when
added to PPP containing 5 pM r-TF, dabigatran at 500 nM
prolonged LT and TTP by 2.89- and 1.88-fold, respectively,
compared to the untreated control, and moderately decreased PH
by 24.1%. In contrast, rivaroxaban at 500 nM prolonged LT and
TTP by 3.44- and 4.25-fold, respectively, compared to the control
and reduced PH by 80.0% (Fig. 3B, Table 2). Taken together,
these results demonstrate that rivaroxaban exerts extensive PH
reduction at lower concentrations. This inhibition follows the
saturable Michaelis-Menten kinetics, while dabigatran demon-
strates more linear reduction in PH at both thromboplastin levels
(Fig. 3A, 3B). LT and TTP were prolonged in a concentration-
dependent manner, and this effect did not depend on thrombo-
plastin level for rivaroxaban.
(ii) TG in PRP. In the TG assay using PRP, both dabigatran
and rivaroxaban prolonged LT and TTP, and reduced PH in a
concentration-dependent manner (Fig. 4). Relative to the untreat-
ed control, dabigatran and rivaroxaban at 500 nM prolonged both
LT (3.18- and 3.56-fold, respectively) and TTP (1.60- and 2.53-
fold, respectively) and decreased PH by 42.5% and 67.1%,
respectively (Fig. 4A, Table 3). The ETP also had tendency to
decrease, but accurate calculation for this effect was impossible at
some concentrations. After addition of aspirin and AR-C66096 to
PRP, LT and TTP values were minimally prolonged without
essential changes in PH value (Fig. 4B, Table 3). Similarly, no
statistically significant changes in any of the TG parameters were
observed by the addition of aspirin and AR-C66096 to the
dabigatran or rivaroxaban treatment of PRP (Fig. 4B, Table 3).
Discussion
Our present data demonstrate that dabigatran and rivaroxaban
possess distinctive antithrombotic properties under arterial and
venous shear conditions. Anticoagulant activities of both drugs
appear to be influenced by localized tissue thromboplastin, and by
the presence of antiplatelet agents. Notably, antithrombotic
efficacies of dabigatran and rivaroxaban under flow conditions
markedly differ from those of static coagulation tests, particularly
in the presence of antiplatelet agents.
In the microchip-based flow chamber analysis, dabigatran
efficiently reduced fibrin-rich platelet thrombus formation, and
delayed capillary occlusion (OT) more extensively than rivarox-
aban at both tested shear rates (Fig. 1A, B). The formation of
fibrin-rich platelet thrombi was only weakly inhibited by aspirin
and AR-C66096 in non-anticoagulated whole blood; however,
these two antiplatelet agents enhanced the antithrombotic
Table 1. Effects of Dabigatran and Rivaroxaban on TG in PPP
(low tissue factor).
Treatment LT (min) TTP (min) PH (nM) ETP (min x nM)
Control 5.860.6 10.660.4 117.1621.2 14536199
Dabi 250 nM 18.762.1*** 22.462.2*** 141.0624.9 13526197
Dabi 500 nM 30.463.1*** 34.963.3*** 87.8610.7* 832663**1
Dabi 1000 nM 40.566.2*** 49.566.7*** 22.667.2** 118683**1
Riva 250 nM 15.560.3*** 31.861.2*** 34.161.0** 621616**1
Riva 500 nM 17.760.5*** 30.565.3** 19.968.2** 343686***1
Riva 1000 nM 22.762.2*** 50.663.3*** 12.661.8*** 63653***1
TG, thrombin generation triggered by 1 pM recombinant tissue factor; PPP,
platelet-poor plasma; Dabi, dabigatran; Riva, rivaroxaban; LT, lag time; TTP, time
to peak of TG; PH, peak height of TG; ETP, endogenous thrombin generation
potential.
Data are shown as the mean 6 SD. * P,0.05, ** P,0.01, and *** P,0.001 vs.
control.
1indicates that, since TG curves did not come down to the baseline within 60
min, ETP values were calculated by setting the start tail at 60min.
doi:10.1371/journal.pone.0086491.t001
Table 2. Effects of Dabigatran and Rivaroxaban on TG in PPP
(high tissue factor).
Treatment LT (min) TTP (min) PH (nM) ETP (min x nM)
Control 2.760.4 5.260.5 329.4624.7 19426152
Dabi 250 nM 5.661.0** 7.761.1** 313.0630.9 17926207
Dabi 500 nM 7.861.3*** 9.861.2*** 250.1627.4*** 13076147***
Dabi 1000 nM 11.661.8*** 13.861.7*** 85.3612.4*** 574654***
Riva 250 nM 7.960.5*** 18.660.9*** 89.063.6*** 1616621*
Riva 500 nM 9.360.3*** 22.161.1*** 66.061.7*** 1436632**
Riva 1000 nM 10.660.4*** 25.161.1*** 48.361.9*** 982644***1
TG, thrombin generation triggered by 5 pM recombinant tissue factor; PPP,
platelet-poor plasma; Dabi, dabigatran; Riva, rivaroxaban; LT, lag time; TTP, time
to peak of TG; PH, peak height of TG; ETP, endogenous thrombin generation
potential.
Data are shown as the mean 6 SD. * P,0.05, ** P,0.01, and *** P,0.001 vs.
control.
1indicates that, since TG curves did not come down to the baseline within 60
min, ETP values were calculated by setting the start tail at 60min.
doi:10.1371/journal.pone.0086491.t002
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efficacies of both anticoagulants (Fig. 1C, D). Dabigatran
exhibited more potent antithrombotic activity in combination
with aspirin and AR-C66096 than that of rivaroxaban under
arterial shear flow (600 s21). These findings are in contrast with
the anticoagulant efficacies of dabigatran and rivaroxaban shown
in the TG measurements. In plasma without platelets, low
concentrations of dabigatran decreased PH in a concentration-
dependent manner more slowly than corresponding concentra-
tions of rivaroxaban (Fig. 3A, B). Our TG data in PPP are in
agreement with previously published data by Furugohri, et al. [16],
and Marlu, et al. [17] Both studies demonstrated more extensive
suppression of peak TG with anti-Xa agents (edoxaban or
rivaroxaban) compared to the anti-IIa agents (melagatran,
lepirudin or dabigatran).
Conversely, our TG data in platelet-rich plasma demonstrated
that dabigatran and rivaroxaban similarly suppressed TG peak
levels (Fig. 4). When TG is triggered without exogenous
phospholipids, thrombin-mediated platelet activation becomes an
important source of phospholipids. Rivaroxaban inhibits FXa and
FXa-FVa complexes on activated platelets [18], whereas dabiga-
tran impairs platelet-surface mediated TG by blocking platelet
activation via PAR1 or PAR4 [19]. Thrombin-mediated platelet
activation is more critical under flow conditions, particularly in the
presence of antiplatelet agents, as our flow-chamber experiments
demonstrated more extensive thrombus suppression using dabiga-
tran than rivaroxaban.
Our present confocal microscopy analysis was performed to
characterize different compositions of thrombi formed in the
presence dabigatran alone or in combination with dual platelet
inhibition with aspirin and AR-C66096. Intraluminal platelet
deposition was decreased in the presence of dabigatran compared
to non-anticoagulated control (Fig. 2A, B), and further reduction
of platelet deposition was observed with dabigatran and dual
antiplatelet agents (Fig. 2C). Inhibiting collagen-induced platelet
procoagulant activity was also demonstrated with anti-IIa bivalir-
udin within clinical concentrations (mean 2.7 mM) via PAR1
inhibition [20]. In our flow-chamber model, thromboplastin and
collagen are initial triggers for thrombus formation, but sequential
activations of platelet receptors for collagen, TXA2, ADP and
PARs are also reflected [21,22]. In contrast to the improved
antithrombotic efficacies of dabigatran and rivaroxaban in
combination with antiplatelet agents under arterial shear, our
static TG model in PRP failed to exhibit the combined effects of
anticoagulant and antiplatelet agents (Fig. 4, Table 3).
In our flow-chamber model, exposure to thromboplastin
(extrinsic pathway) and collagen is limited to the platelets and
plasma flowing adjacent to the capillary wall. Subsequent
thrombus growth depends on local recruitment and activation of
Figure 4. Effects of Dabigatran and Rivaroxaban on TG in PRP. The inhibitory effects of dabigatran (Dabi) and rivaroxaban (Riva) on thrombin
generation (TG) in platelet-rich plasma in the absence (panel A) and presence of 100 mM aspirin (Asp) together with 1 mM AR-C66096 (AR-C) (panel
B) were calculated using ThrombinoscopeTM. Typical TG patterns obtained in one of the experiments are shown.
doi:10.1371/journal.pone.0086491.g004
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platelets, and thrombin-mediated feedback activation of the
intrinsic pathway [23]. Procoagulant activities of FXa and
thrombin are also limited by blood flow, which prevent their
efficient interaction with substrates [24]. In static plasma
coagulation model, initial TG is highly dependent on TF level,
and FXa is its limiting step [25]. The contrasting data between
flow and static conditions qualitatively confirm that low PH in
static TG is not a prerequisite for effective antithrombotic activity
in vivo.
Our in vitro data in the flow chamber experiments are
corroborated by the increased antithrombotic, and potentially
hemorrhagic effects of dual antiplatelet therapy with anti-IIa or
anti-Xa agents in patients with ACS [8–10]. The mono-
antiplatelet therapy with aspirin combined with an anti-IIa,
ximelagatran was reported to decrease the recurrent cardiovas-
cular events without a major increase in bleeding events [7].
Conversely, the addition of dabigatran to dual antiplatelet
therapy increased minor and major bleeding complications, but
it did not improve clinical outcomes of the patients with acute
coronary syndromes [9]. The combination of low-dose rivarox-
aban (2.5 mg twice daily) and antiplatelet therapy significantly
reduced death from cardiovascular causes and myocardial
infarction in patients with recent ACS [10], but the incidence
of bleeding complications, including intracranical hemorrhage,
was increased [10].
A few limitations of the present study should be mentioned.
First, endothelial cells are excluded form the microchip-based
flow chamber system, and therefore it is not feasible to evaluate
interactions between anticoagulants and endothelial elements
(e.g., thrombomodulin) [16]. Second, subendothelial TF expres-
sion varies among vascular beds, a property that may in part
explain the increased gastrointestinal bleeding, but the decreased
incidence of hemorrhagic stroke, associated with dabigatran
relative to warfarin [26]. Although two different concentrations of
thromboplastin were tested in our study, our in vitro results cannot
be directly inferred to clinical efficacy or hemorrhagic risk.
Increasing numbers of antiplatelet and anticoagulant agents are
becoming available for clinical use [5,27], but few monitoring
techniques exist for the assessment of various antithrombotic
agents and their combinations [28]. The ability of microchip-
based flow chamber systems to rapidly evaluate and characterize
antithrombotic efficacies of drug combinations under flow
conditions is potentially useful in the dose adjustment, and the
selection of optimal agents. Future clinical studies using ex vivo
blood samples collected from patients receiving antithrombotic
therapies are warranted to correlate pertinent analytical param-
eters of the flow system with clinical thrombosis and/or bleeding
outcomes.
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Figure S1 Schematic diagrams of the microchip flow
chamber system. (A) The microchip. (B) The analytical set up.
(TIF)
Video S1 Video images of the thrombus formation
process. Thrombus formation in the presence and absence of
dabigatran, Aspirin and AR-C66096.
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Table 3. Effects of Dabigatran and Rivaroxaban on TG in PRP in the presence and absence of Aspirin and AR-C66096.
Treatment LT (min) TTP (min) PH (nM) ETP (min x nM)
Control 6.860.8 19.761.8 92.1623.7 15476297
Dabi 250 nM 18.665.4*** 27.967.3 69.2620.6 128663521
Dabi 500 nM 21.665.3*** 31.566.8 53.065.8*** 10126120
Dabi 1000 nM 30.265.6*** 41.864.8*** 23.066.9*** 5656136***1
Asp + AR-C 9.463.2 23.362.8 91.2629.5 15046252
Dabi 250 nM + Asp+AR-C 21.164.5*** 35.768.1 52.2613.6*** 11956365
Dabi 500 nM + Asp+AR-C 26.2610.2*** 38.0610.6 47.869.0*** 110161541
Dabi 1000 nM + Asp+AR-C 35.166.3*** 49.968.2*** 22.068.4*** 4656197***1
Riva 250 nM 20.164.0*** 39.063.6** 44.766.8*** 114262291
Riva 500 nM 24.266.2*** 49.8610.5*** 30.367.8*** 98063511
Riva 1000 nM 31.269.8*** 68.7617.1*** 20.867.7*** 5436320***1
Riva 250 nM +Asp+AR-C 22.263.8*** 45.765.9*** 44.469.3*** 115667941
Riva 500 nM + Asp+AR-C 26.765.3*** 56.5612.2*** 31.268.0*** 9016278*1
Riva 1000 nM + Asp+AR-C 30.867.0*** 78.6624.4*** 18.169.3*** 4806410***1
TG, thrombin generation triggered by 1 pM recombinant tissue factor; PRP, platelet-rich plasma; Asp, aspirin 100 mM; AR-C66096, 1 mM; Dabi, dabigatran; Riva,
rivaroxaban; LT, lag time; TTP, time to peak of TG; PH, peak height of TG; ETP, endogenous thrombin generation potential.
Data are shown as the mean 6 SD. * P,0.05, ** P,0.01, and *** P,0.001 vs. Asp+AR-C.
1indicates that, since TG curves did not come down to the baseline within 120 min, ETP values were calculated by setting the start tail at 120min.
doi:10.1371/journal.pone.0086491.t003
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